Company news
Gyre Therapeutics, Inc. (NASDAQ:GYRE) news
Gyre Therapeutics, Inc. news releases on 6ix. Latest, Aug 1, 2022: Catalyst Biosciences Publishes New Investor Presentation
Press releases — page 2
Catalyst Biosciences Publishes New Investor Presentation
July 31, 2022
Catalyst Biosciences Announces Support from Largest Single Stockholder
July 31, 2022
Catalyst Biosciences Sends Letter to Stockholders
July 18, 2022
Catalyst Biosciences Comments on Favorable Delaware Court of Chancery Ruling
July 5, 2022
Catalyst Biosciences Announces Plan to Distribute Cash to Stockholders
June 28, 2022
Catalyst Biosciences Sells Complement Portfolio for $60 Million
May 22, 2022
Catalyst Biosciences Reports First Quarter 2022 Operating & Financial Results
May 8, 2022
Catalyst Biosciences Reports Fourth Quarter and Year-end 2021 Operating & Financial Results and Provides a Corporate Update
March 30, 2022
Catalyst Biosciences Regains Rights to CB 2782-PEG for the Treatment of Dry AMD Expands CBIO’s Complement Portfolio in Ophthalmology
March 14, 2022
Catalyst Biosciences Engages Perella Weinberg Partners to Assist the Company in Exploring Strategic Alternatives
February 16, 2022
Catalyst Biosciences Receives Rare Pediatric Disease Designation for CB 4332 for the Treatment of CFI Deficiency
January 24, 2022
Catalyst Biosciences to Present at the Piper Sandler 33rd Annual Virtual Healthcare Conference
November 21, 2021
Catalyst Biosciences Announces Change in Corporate Strategy
November 11, 2021
Catalyst Biosciences Announces CFI Variant Presentations at Two Upcoming Scientific Conferences
October 28, 2021
Catalyst Biosciences Announces Chief Financial Officer Transition
October 12, 2021
FDA Grants Catalyst Biosciences Orphan Drug Designation for MarzAA for the Treatment of Factor VII Deficiency
September 27, 2021
Catalyst Biosciences to Present at the Cantor Global Healthcare Conference
September 23, 2021
Catalyst Biosciences Participating in a Fireside Chat with LifeSci Capital
September 14, 2021
Catalyst Biosciences Announces Oral and Poster Presentations at the International Conference on Complement Therapeutics
September 8, 2021
Catalyst Biosciences Announces Appointment of Jeanne Jew to its Board of Directors
September 7, 2021
Catalyst Biosciences Reports Second Quarter 2021 Operating & Financial Results and Provides a Corporate Update
August 4, 2021
Catalyst Biosciences Announces First Patient Screened for CFI deficiency in its CB 4332 Screening and Natural History of Disease Studies
July 21, 2021
Catalyst Biosciences Presents Four Posters at the International Society for Thrombosis and Haemostasis (ISTH) 2021 Virtual Congress
July 18, 2021
Catalyst Biosciences Announces Key Leadership Changes in its Ongoing Transition to an Integrated Protease Medicines Company
July 13, 2021
Catalyst Biosciences Announces Presentations at the International Society on Thrombosis and Haemostasis
July 5, 2021
Catalyst Biosciences to Host Research and Development Day on CB 4332 and Complement Programs
June 30, 2021
Catalyst Biosciences Receives FDA Fast Track Designation for Subcutaneous MarzAA for the Treatment of Episodic Bleeding in Factor VII Deficiency
June 27, 2021
Catalyst Biosciences to Participate in Two Upcoming Investor Conferences
June 9, 2021
Catalyst Biosciences Announces First Patient Dosed in Marzeptacog Alfa (Activated) Phase 1/2 Study in Factor VII Deficiency, Glanzmann Thrombasthenia and Hemophilia A treated with Hemlibra
May 17, 2021
Catalyst Biosciences to Present at the Truist Securities Life Sciences Summit
May 12, 2021
Catalyst Biosciences Reports First Quarter 2021 Operating & Financial Results and Provides a Corporate Update
May 5, 2021
Catalyst Biosciences Announces First Patient Dosed in Pivotal Phase 3 Registration Study of SQ MarzAA in Individuals with Hemophilia A or B with Inhibitors
May 4, 2021
Catalyst Biosciences Announces Publication of CB 2679d Preclinical FIX Gene Therapy Data in Blood, the Journal of the American Society of Hematology
April 18, 2021
Catalyst Biosciences Expands its Protease Medicines Patent Portfolio of Complement Factor 3 Degraders
April 11, 2021
Catalyst Biosciences to Present at the 20th Annual Needham Virtual Healthcare Conference
April 6, 2021
Catalyst Biosciences Reports Fourth Quarter and Full-Year 2020 Operating & Financial Results and Provides a Corporate Update
March 3, 2021
Catalyst Biosciences to Present at the 42nd Annual Raymond James Institutional Investors Conference
February 17, 2021
Catalyst Biosciences Announces Partial Exercise and Closing of Over-Allotment Option in Public Offering of Common Stock
February 10, 2021
Catalyst Biosciences Presents Pre-clinical SQ Treatment of Bleeds Data from its Marzeptacog alfa (activated) (MarzAA) Program at the 14th Annual EAHAD Congress
February 2, 2021
Catalyst Biosciences Announces Closing of Public Offering of Common Stock
January 28, 2021
Catalyst Biosciences Announces Pricing of Public Offering of Common Stock
January 26, 2021
Catalyst Biosciences Announces Proposed Public Offering of Common Stock
January 25, 2021
Catalyst Biosciences Announces Poster Presentations at the EAHAD 2021 Virtual Congress
January 19, 2021
Catalyst Biosciences Presents Crimson 1 Phase 3 Study Design at the 62nd Annual American Society of Hematology Conference
December 6, 2020
Catalyst Biosciences Hosting Research & Development Call on Systemic Complement Regulator Programs
December 2, 2020
Catalyst Biosciences Receives FDA Fast Track Designation for Subcutaneous MarzAA for the Treatment of Episodic Bleeding in Hemophilia A or B with Inhibitors
December 1, 2020
Catalyst Biosciences to Present at 32nd Annual Piper Sandler Virtual Healthcare Conference
November 23, 2020
Catalyst Biosciences Reports Third Quarter 2020 Operating & Financial Results and Provides a Corporate Update
November 4, 2020
Catalyst Biosciences Announces Poster Presentation at the 62nd Annual American Society of Hematology Conference
November 4, 2020
Catalyst Biosciences to Present at Stifel 2020 Virtual Healthcare Conference
November 2, 2020